What is LENZ Therapeutics, Inc.'s market cap?

LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $178.7M and trades on NASDAQ.

Who are LENZ Therapeutics, Inc.'s competitors?

LENZ Therapeutics, Inc.'s key competitors include Bausch + Lomb, AbbVie, Amneal Pharmaceuticals, and others. These companies compete in similar markets and product categories.

Who does LENZ Therapeutics, Inc. partner with?

LENZ Therapeutics, Inc.'s notable partners include Merck.

Where is LENZ Therapeutics, Inc. headquartered?

LENZ Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.

LENZ Therapeutics, Inc.

LENZ

LENZ Therapeutics is a commercial-stage pharmaceutical company specializing in the development and commercialization of innovative ophthalmic therapies.

Market cap

$178.72M-79.4%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$1.9MBeat by $142.1K EPS-$1.32Miss by $0.22

Read the full report

Next report

Jul 29, 2026 (Today)

Revenue estimate$2.4M

EPS estimate-$1.05

Competitors

By market cap

AbbVie$453.91B+36.3%

Alcon$32.8B-26.4%

Bausch + Lomb$5.8B+13.7%

Amneal Pharmaceuticals, Inc.$5.8B+126%

HRO

Harrow$1.4B+9.1%

Outlook Therapeutics, Inc.$199.2M+131%

LENZ Therapeutics, Inc.$178.7M-79.8%

Aldeyra Therapeutics$95.6M-70.0%

By revenue growth

Amneal Pharmaceuticals, Inc.+7.6%

By net margin

AbbVie5.79%-1.5pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

Bausch + Lomb-3.21%+2.4pp

HRO

Harrow-19.75%+1.0pp

Profile

LENZ Therapeutics is a commercial-stage pharmaceutical company specializing in the development and commercialization of innovative ophthalmic therapies. Its core value proposition is centered on VIZZ, the first FDA-approved aceclidine-based eye drop designed to treat presbyopia by improving near vision without compromising distance vision. The company aims to capture a significant share of the vision correction market by providing a pharmacological alternative to reading glasses.

Competitive position

LENZ is a first-mover in aceclidine-based treatments for presbyopia, holding a robust intellectual property portfolio with patent protection extending to 2044.

GeographiesUnited States, Global

Customer segmentsEye care professionals, Retail pharmacy chains, Presbyopic patients

Business modelDirect-to-consumer marketing, B2B2C, Licensing and distribution

SuppliersContract manufacturing organizations, Active pharmaceutical ingredient suppliers, Clinical research organizations

CustomersOptometry clinics, Ophthalmology practices, Retail pharmacies, E-pharmacy platforms

CountryUnited States of America

Listed2024

CEOEvert Schimmelpennink

SectorHealthcare

IndustryBiotechnology

Websitelenz-tx.com

FilingsSEC EDGAR

Questions, answered.

What is LENZ Therapeutics, Inc.'s market cap?: LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $178.7M and trades on NASDAQ.
Who are LENZ Therapeutics, Inc.'s competitors?: LENZ Therapeutics, Inc.'s key competitors include Bausch + Lomb, AbbVie, Amneal Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does LENZ Therapeutics, Inc. partner with?: LENZ Therapeutics, Inc.'s notable partners include Merck.
Where is LENZ Therapeutics, Inc. headquartered?: LENZ Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.